Considering the multiple benefits of anti-cancer effects and the protective functions of Ang 1–7/MasR signaling, the suggestion of balancing Mas receptor activity with agonist substances may be a potential therapeutic option in breast cancer [235]. Here, ANGPT1 is linked to breast carcinoma.